Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.61 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027548 | 0.88 | HPGD (0.68) | HPGDHRH3HIF1AEPAS1NPC1 | |
| SCHEMBL18413640 | 0.86 | HPGD (0.66) | HPGDHRH3HIF1AEPAS1NPC1 | |
| SCHEMBL1177221 | 0.86 | HPGD (0.66) | HPGDHRH3HIF1AEPAS1NPC1 | |
| SCHEMBL426993 | 0.86 | HPGD (0.66) | HPGDHRH3HIF1AEPAS1NPC1 | |
| Hydrochloric Acid SCHEMBL27789112 | 0.86 | HPGD (0.66) | HPGDHRH3HIF1AEPAS1NPC1 | |
| SCHEMBL540760 | 0.85 | HRH3 (0.65) | HPGDHRH3HIF1AEPAS1NPC1 | |
| SCHEMBL2912823 | 0.85 | HPGD (0.64) | HPGDHRH3HIF1AEPAS1NPC1 | |
| Hydrochloric Acid SCHEMBL3858785 | 0.85 | HPGD (0.64) | HPGDHRH3HIF1AEPAS1NPC1 | |
| Hydrochloric Acid SCHEMBL1177256 | 0.85 | HPGD (0.64) | HPGDHRH3HIF1AEPAS1NPC1 | |
| SCHEMBL13244639 | 0.83 | HPGD (0.62) | HPGDHRH3HIF1AEPAS1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | claimed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | claimed |
| US-7135502-B1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-11-14 | — | — | US | disclosed |
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-06-15 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1140745-B1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1140745-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040529-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-13 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HPGD 554/4885HRH3 142/4885HIF1A 881/4885 |
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | NR1H3, NR1H2, NR1H4 | HPGD 2462/4885HRH3 27/4885HIF1A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.